ACAD ACADIA Pharmaceuticals Inc.

53.28
-1.45  -3%
Previous Close 54.73
Open 54.88
52 Week Low 30.02
52 Week High 58.72
Market Cap $8,470,352,475
Shares 158,978,087
Float 158,383,023
Enterprise Value $8,433,124,560
Volume 1,086,839
Av. Daily Volume 1,052,295
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Pimavanserin - Harmony
Alzheimer’s disease psychosis
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Trofinetide
Rett Syndrome
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Pimavanserin - Advance-2
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3
Phase 3
Phase 3 trial initiated 3Q 2020.
ACP-044
Pain
Phase 2
Phase 2
Phase 2 trial to be initiated 1H 2021.
Pimavanserin - CLARITY-2 and CLARITY-3
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - July 20, 2020.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Phase 3
Phase 3
Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Approved
Approved
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Phase 2
Phase 2
Announced October 4, 2017 that trial will be discontinued.

Latest News

  1. Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time.

    The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through December 15, 2020.

    About Acadia Pharmaceuticals

    Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved…

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will present at the Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020, at 3:20 p.m. Eastern Time.

    The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through December 15, 2020.

    About Acadia Pharmaceuticals

    Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

    View Full Article Hide Full Article
  2. - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020.

    "This quarter we drove strong performance through the continued growth of new prescribers with more patients benefitting from NUPLAZID® treatment for their Parkinson's disease psychosis and remain on-track with our supplemental NDA for the treatment of dementia-related psychosis with a PDUFA date of April 3, 2021," said Steve Davis, Acadia's Chief Executive Officer. "We continue to advance…

    - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020.

    "This quarter we drove strong performance through the continued growth of new prescribers with more patients benefitting from NUPLAZID® treatment for their Parkinson's disease psychosis and remain on-track with our supplemental NDA for the treatment of dementia-related psychosis with a PDUFA date of April 3, 2021," said Steve Davis, Acadia's Chief Executive Officer. "We continue to advance our late-stage programs and invest in new opportunities through business development, highlighted by our recent acquisition of CerSci Therapeutics which expands our clinical pipeline with an innovative first-in-class, non-opioid, acute and chronic pain program."

    Company Updates

    • New clinical analyses across multiple studies of pimavanserin are being presented at this week's 13th Clinical Trials on Alzheimer's Disease (CTAD) meeting, including:
      • Oral presentation by Dr. Clive Ballard, University of Exeter Medical School: "Impact of Pimavanserin on Cognitive Measures in Patients with Neurodegenerative Disease: Results from 4 Placebo-Controlled Clinical Studies."
      • Poster presentation by Dr. Daniel Weintraub, Perelman School of Medicine at the University of Pennsylvania: "Impact of Pimavanserin Treatment on Motor Function in Patients with Neurodegenerative Disease: Results from 3 Clinical Studies."
    • In October, Acadia announced a partnership with The Lewy Body Dementia Association (LBDA) on the release of a disease education adaptation of the new documentary Robin's Wish©. The film is titled, "SPARK - Robin Williams and his Battle with Lewy Body Dementia©," and will be available to academic research institutions and universities as part of educational programming for healthcare professionals.
    • In October, Acadia presented a poster titled "Healthcare Resource Utilization and Associated Costs for Dementia Patients with Psychosis: A Medicare Database Study," at the Academy of Managed Care Pharmacy's (AMCP) Nexus conference, and received a Silver ribbon based on its relevance, originality, quality, bias and clarity of results.
    • In August, Acadia acquired CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. Acadia plans to initiate a Phase 2 program with the lead compound, ACP-044, in the first half of 2021.
    • Appointed Dr. Gudarz Davar as Executive Vice President and Head of Research and Development, reporting to Serge Stankovic, M.D., M.S.P.H., President of Acadia.
    • Elizabeth (Betsy) Garofalo, M.D. was appointed to the Acadia Board of Directors.

    Financial Results

    Revenue

    Net sales of NUPLAZID (pimavanserin) were $120.6 million for the three months ended September 30, 2020, an increase of 27% as compared to $94.6 million reported for the three months ended September 30, 2019. For the nine months ended September 30, 2020 and 2019, Acadia reported net product sales of $320.7 million and $240.8 million, respectively.

    Research and Development

    Research and development expenses for the three months ended September 30, 2020 were $120.1 million, compared to $62.6 million for the same period of 2019. This increase was primarily due to $52.8 million in upfront consideration and transaction expenses related to the acquisition of CerSci Therapeutics. For the nine months ended September 30, 2020 and 2019, research and development expenses were $257.0 million and $182.9 million, respectively. This increase was primarily due to the acquisition of CerSci Therapeutics and the upfront payment to Vanderbilt University for the M1 PAM program.

    Selling, General and Administrative

    Selling, general and administrative expenses for the three months ended September 30, 2020 were $81.6 million, compared to $72.7 million for the same period of 2019. For the nine months ended September 30, 2020 and 2019, selling, general and administrative expenses were $267.9 million and $233.8 million, respectively. This increase was primarily due to increased advertising and promotional costs as well as an increase in personnel and related costs.

    Net Loss

    For the three months ended September 30, 2020, Acadia reported a net loss of $84.7 million, or $0.54 per common share, compared to a net loss of $42.0 million, or $0.29 per common share, for the same period in 2019. The net losses for the three months ended September 30, 2020 and 2019 included $21.4 million and $22.0 million, respectively, of non-cash stock-based compensation expense. For the nine months ended September 30, 2020, Acadia reported a net loss of $214.8 million, or $1.37 per common share, compared to a net loss of $182.2 million, or $1.26 per common share, for the same period in 2019. The net losses for the nine months ended September 30, 2020 and 2019 included $63.2 million and $62.5 million, respectively, of non-cash stock-based compensation expense.

    Cash and Investments

    At September 30, 2020, Acadia's cash, cash equivalents, and investment securities totaled $644.4 million, compared to $697.4 million at December 31, 2019.

    2020 Financial Guidance

    • Acadia reiterates its NUPLAZID net sales guidance of $430 to $450 million.
    • GAAP R&D guidance is increased to $325 to $340 million from the previous range of $265 to $280 million, primarily as a result of the $52.8 million upfront and transaction expenses associated with the acquisition of CerSci Therapeutics.
    • GAAP SG&A guidance is decreased to $385 to $400 million from the previous range of $400 to $420 million.
    • Non-cash stock-based compensation expense guidance is decreased to $80 to $90 million from the previous range of $90 to $100 million.
    • 2020 year-end cash, cash equivalents, and investment securities guidance of $570 to $590 million is unchanged.

    Conference Call and Webcast Information

    Acadia management will review its third quarter financial results and operations via conference call and webcast today at 4:30 p.m. Eastern Time. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 6266016). A telephone replay of the conference call may be accessed through November 18, 2020 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 6266016). The conference call also will be webcast live on Acadia's website, www.acadia-pharm.com, under the investors section and will be archived there until December 2, 2020.

    About NUPLAZID® (pimavanserin)

    NUPLAZID is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting 5-HT2A receptors that are thought to play an important role in Parkinson's disease psychosis. NUPLAZID is an oral medicine taken once a day with a recommended dose of 34 mg. NUPLAZID is not FDA-approved for any other neuropsychiatric disorders. Acadia discovered and developed this new chemical entity and holds worldwide rights to develop and commercialize NUPLAZID.

    About Trofinetide

    Trofinetide is an investigational drug. It is a novel synthetic analog of the amino-terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function. In the central nervous system, IGF-1 is produced by both of the major types of brain cells – neurons and glia. IGF-1 in the brain is critical for both normal development and for response to injury and disease. Trofinetide has been granted Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in Europe for both Rett syndrome and Fragile X syndrome.

    About Acadia Pharmaceuticals

    Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

    Forward-Looking Statements

    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements related to: the potential opportunity for future growth in sales of NUPLAZID; the timing of ongoing and future clinical studies for pimavanserin; the development and commercialization of trofinetide, ACP-044 and the M1 PAM program; unanticipated impacts of COVID-19 on Acadia's business, including its commercial sales operations, current and planned clinical trials, supply chain, and guidance for full-year 2020 NUPLAZID net sales and certain expense line items. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the uncertainty of future commercial sales and related items that would impact net sales during 2020, the risks and uncertainties inherent in drug development, approval and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Acadia's annual report on Form 10-K for the year ended December 31, 2019 as well as Acadia's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    Copyright 2020 by Tiburon Sunrise, LLC

     

    ACADIA PHARMACEUTICALS INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share amounts)

    (Unaudited)

     

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

     

    2020

     

    2019

     

    2020

     

    2019

    Revenues

     

     

     

     

     

     

     

     

     

     

     

     

    Product sales, net

    $

    120,577

     

    $

    94,586

     

    $

    320,748

     

    $

    240,750

     

    Total revenues

     

    120,577

     

     

    94,586

     

     

    320,748

     

     

    240,750

     

    Operating expenses

     

     

     

     

     

     

     

     

     

     

     

     

    Cost of product sales, license fees and royalties (1)

     

    4,801

     

     

    4,689

     

     

    15,249

     

     

    14,264

     

    Research and development (1)

     

    120,083

     

     

    62,622

     

     

    257,014

     

     

    182,865

     

    Selling, general and administrative (1)

     

    81,592

     

     

    72,696

     

     

    267,909

     

     

    233,767

     

    Total operating expenses

     

    206,476

     

     

    140,007

     

     

    540,172

     

     

    430,896

     

    Loss from operations

     

    (85,899

    )

     

    (45,421

    )

     

    (219,424

    )

     

    (190,146

    )

    Interest income, net

     

    1,242

     

     

    2,432

     

     

    6,056

     

     

    7,893

     

    Other (expense) income

     

    (202

    )

     

    747

     

     

    (1,262

    )

     

    506

     

    Loss before income taxes

     

    (84,859

    )

     

    (42,242

    )

     

    (214,630

    )

     

    (181,747

    )

    Income tax expense

     

    (199

    )

     

    (264

    )

     

    194

     

     

    476

     

    Net loss

    $

    (84,660

    )

    $

    (41,978

    )

    $

    (214,824

    )

    $

    (182,223

    )

    Net loss per common share, basic and diluted

    $

    (0.54

    )

    $

    (0.29

    )

    $

    (1.37

    )

    $

    (1.26

    )

    Weighted average common shares outstanding, basic and diluted

     

    158,129

     

     

    145,906

     

     

    156,683

     

     

    144,741

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (1) Includes the following stock-based compensation expense

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Cost of product sales, license fees and royalties

    $

    495

     

    $

    372

     

    $

    2,087

     

    $

    2,344

     

    Research and development

    $

    7,953

     

    $

    8,680

     

    $

    23,645

     

    $

    24,461

     

    Selling, general and administrative

    $

    12,924

     

    $

    12,971

     

    $

    37,495

     

    $

    35,697

     

     

    ACADIA PHARMACEUTICALS INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

     

     

     

    September 30,

    2020

     

    December 31,

    2019

     

     

    (unaudited)

     

     

     

    Assets

     

     

     

     

    Cash, cash equivalents and investment securities

    $

    644,441

    $

    697,429

    Accounts receivable, net

     

    46,344

     

    35,781

    Interest and other receivables

     

    1,440

     

    2,093

    Inventory

     

    7,979

     

    6,341

    Prepaid expenses

     

    30,009

     

    18,606

    Total current assets

     

    730,213

     

    760,250

    Property and equipment, net

     

    8,427

     

    3,180

    Operating lease right-of-use assets

     

    48,232

     

    9,524

    Intangible assets, net

     

    1,477

     

    2,585

    Restricted cash

     

    5,770

     

    4,787

    Other assets

     

    1,545

     

    2,857

    Total assets

    $

    795,664

    $

    783,183

    Liabilities and stockholders' equity

     

     

     

     

    Accounts payable

    $

    3,471

    $

    7,222

    Accrued liabilities

     

    88,385

     

    67,604

    Total current liabilities

     

    91,856

     

    74,826

    Operating lease liabilities

     

    45,343

     

    6,361

    Other long-term liabilities

     

    3,598

     

    2,861

    Total liabilities

     

    140,797

     

    84,048

    Total stockholders' equity

     

    654,867

     

    699,135

    Total liabilities and stockholders' equity

    $

    795,664

    $

    783,183

     

    View Full Article Hide Full Article
  3. Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.

    Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patients with neuropsychiatric symptoms related to neurodegenerative diseases, including dementia-related psychosis. Other presentations include a comprehensive literature review of current use of antipsychotic treatment for dementia-related psychosis, an analysis of mortality risk and…

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.

    Scientific presentations include those investigating pimavanserin treatment and its impact on cognition and motor function in patients with neuropsychiatric symptoms related to neurodegenerative diseases, including dementia-related psychosis. Other presentations include a comprehensive literature review of current use of antipsychotic treatment for dementia-related psychosis, an analysis of mortality risk and need for long-term care for patients with dementia-related psychosis versus patients with dementia only, and assessments of efficacy and safety of pimavanserin in dementia-related psychosis.

    CTAD Accepted Scientific Presentations include:

    Oral Presentations:

    • Oral Presentation (OC31): Impact of Pimavanserin on Cognitive Measures in Patients with Neurodegenerative Disease: Results from 4 Placebo-Controlled Clinical Studies on Friday, November 6, 10:45 – 11:00 a.m. ET. Presenting author: Clive Ballard, MBChB, University of Exeter Medical School, Exeter, United Kingdom.
    • Oral Presentation (OC17): Relationship Between Pimavanserin Exposure and Psychosis Relapse in Patients with Dementia-Related Psychosis: Clinical Results and Modeling Analysis from the Phase 3 HARMONY Study on Thursday, November 5, 10:30 – 10:45 a.m. ET. Presenting author: Mona Darwish, Acadia Pharmaceuticals Inc.

    Poster Presentations:

    • Poster Presentation (P75): Impact of Pimavanserin Treatment on Motor Function in Patients with Neurodegenerative Disease: Results from 3 Clinical Studies. Presenting author: Daniel Weintraub, M.D., Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
    • Poster Presentation (P21): Frequency of Antipsychotic-Associated Adverse Events with Pimavanserin Treatment in Patients with Dementia-Related Psychosis. Presenting author: George Demos, M.D., Acadia Pharmaceuticals Inc.
    • Poster Presentation (P71): Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in the Treatment of Dementia Related Psychosis (DRP): A Systematic Literature Review. Presenting author: Ismaeel Yunusa, An-L-lt-Iks, Inc.
    • Poster Presentation (P69): Mortality Risk and Use of Long-Term Custodial Care for Patients With Dementia and Psychosis Versus Patients With Dementia Only: A Longitudinal, Matched Cohort Analysis of Medicare Claims Data. Presenting author: Nazia Rashid, Acadia Pharmaceuticals Inc.

    About Pimavanserin

    Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID®. Acadia submitted a supplemental new drug application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis on June 3, 2020. The FDA has accepted for filing the sNDA for DRP with a PDUFA date of April 3, 2021. NUPLAZID is not approved for dementia-related psychosis. In addition, Acadia is developing pimavanserin in other neuropsychiatric conditions.

    About Acadia Pharmaceuticals

    Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

    Important Safety Information and Indication for NUPLAZID (pimavanserin)

    Indication

    NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

    Important Safety Information

    WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

    • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
    • NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.
    • Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
    • Warnings and Precautions: QT Interval Prolongation
      • NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics.
      • NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.
    • Adverse Reactions: The common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
    • Drug Interactions:
      • Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
      • Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

    Dosage and Administration

    Recommended dose: 34 mg capsule taken orally once daily, without titration.

    NUPLAZID is available as 34 mg capsules and 10 mg tablets.

    Please read the full Prescribing Information including Boxed WARNING.

    View Full Article Hide Full Article
  4. Acadia to Host Conference Call and Webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.

    The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 6266016). A telephone replay of the conference call may be accessed through November 18, 2020 by dialing 855-859-2056…

    Acadia to Host Conference Call and Webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report third quarter financial results on Wednesday, November 4, 2020, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on Wednesday, November 4, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.

    The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 6266016). A telephone replay of the conference call may be accessed through November 18, 2020 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 6266016). The conference call also will be webcast live on Acadia's website, www.acadia-pharm.com, under the investors section and will be archived there until December 2, 2020.

    About Acadia Pharmaceuticals

    Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

    Forward-Looking Statements

    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia's annual report on Form 10-K for the year ended December 31, 2019 as well as Acadia's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

    View Full Article Hide Full Article
  5. The Lewy Body Dementia Association (LBDA) and Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today an exclusive partnership on the production and release of a disease education adaptation of the new film Robin's Wish©, a documentary detailing the late actor Robin Williams' courageous battle with the neurodegenerative disorder, Lewy body dementia (LBD).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005922/en/

    The film, SPARK - Robin Williams and his Battle with Lewy Body Dementia©, will go beyond describing LBD through the lens of Williams' personal experience and delve into the neurobiology of the disease and associated symptoms to help educate the medical community on…

    The Lewy Body Dementia Association (LBDA) and Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today an exclusive partnership on the production and release of a disease education adaptation of the new film Robin's Wish©, a documentary detailing the late actor Robin Williams' courageous battle with the neurodegenerative disorder, Lewy body dementia (LBD).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005922/en/

    The film, SPARK - Robin Williams and his Battle with Lewy Body Dementia©, will go beyond describing LBD through the lens of Williams' personal experience and delve into the neurobiology of the disease and associated symptoms to help educate the medical community on the second most common form of degenerative dementia. Lewy body dementia is also the most misdiagnosed dementia, and healthcare provider education is needed to enable early recognition, diagnosis and treatment.

    While the full-length film is available on demand and via digital channels, the adaptation, will be available to major academic research institutions and universities as part of educational programming and outreach to the healthcare professionals, the LBD community and general public. The film will be available starting in late October.

    "Robin Williams unknowingly battled LBD and unfortunately, he is not alone. This version of the documentary will not only raise awareness of Lewy body dementia, but reinforce the importance of early symptom recognition, diagnosis and effective management of this devastating disease, and can serve as a key element in our educational offering," said Todd Graham, Executive Director, Lewy Body Dementia Association.

    Approximately 8 million people in the United States are living with dementia, although only half are diagnosed with the condition.1,2,3 In addition to cognitive decline, neuropsychiatric symptoms, including hallucinations, delusions and changes in behavior, are also common. Lewy body dementia affects approximately 1.4 million people and their families in the United States alone.4

    "The use of scientific storytelling is an important opportunity to increase knowledge within the medical community on the need for better diagnostic and disease management solutions. Our goal is to ensure people struggling with LBD get the comprehensive support they need," said Ponni Subbiah, M.D., M.P.H., Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer at Acadia. "We are honored to partner with the LBDA and share a commitment to shine a light on the challenges that people with Lewy body dementia and their caregivers face."

    About Lewy Body Dementia Association

    The Lewy Body Dementia Association (LBDA) is the nation's leading authority on Lewy body dementias (LBD) and is dedicated to continuous outreach, education, research, and support for those affected with LBD and their families. LBD is a progressive brain disease that affects thinking, movement, behavior, and impacts 1.4 million people in the United States.

    About Acadia Pharmaceuticals

    Acadia is trailblazing breakthroughs in neuroscience to elevate life through science. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialize the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

    References

    1 Plassman, BL Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-132.

    2 Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011-2013. Alzheimers Dement. 2017;13(1):28-37.

    3 Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80(19):1778-1783.

    4 Lewy Body Dementia Association www.lbda.org.

    Copyright 2020 by Tiburon Sunrise, LLC

    View Full Article Hide Full Article
View All ACADIA Pharmaceuticals Inc. News